Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 7, 2009, Pages 2253-2258

  Nasser, Nicola J ^a,b,c   Avivi, Aaron ^b   Shafat, Itay ^c   Edovitsky, Evgeny ^d   Zcharia, Eyal ^d   Ilan, Neta ^c   Vlodavsky, Israel ^c   Nevo, Eviatar ^b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Alternative splicing; Angiogenesis; Blind mole rat; Cancer; Heparan sulfate

Indexed keywords

HEPARANASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EXON; EXTRACELLULAR MATRIX; GENETIC VARIABILITY; GLIOMA; MOLE RAT; NONHUMAN; PRIORITY JOURNAL; RAT; RNA SPLICING; TUMOR GROWTH;

ALTERNATIVE SPLICING; ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE; EXTRACELLULAR MATRIX; GLUCURONIDASE; GLYCOSIDE HYDROLASES; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; RATS; SPALAX;

SPALACIDAE; SPALACINAE; SPALAX;

EID: 60549092507     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0812846106     Document Type: Article

References (33)

1. Hacker U, Nybakken K, Perrimon N (2005) Heparan sulphate proteoglycans: The sweet side of development. Nat Rev Mol Cell Biol 6:530-541.
2. Fuster MM, Esko JD (2005) The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat Rev Cancer 5:526-542.
3. Vlodavsky I, et al. (1999) Mammalian heparanase: Gene cloning, expression, and function in tumor progression and metastasis. Nat Med 5:793-802.
4. Hulett MD, et al. (1999) Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5:803-809.
5. Vlodavsky I, Friedmann Y (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108:341-347.
6. Ilan N, Elkin M, Vlodavsky I (2006) Regulation, function, and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38:2018-2039.
7. Vreys V, David G (2007) Mammalian heparanase: What is the message? J Cell Mol Med 11:427-452.
8. Goldshmidt O, et al. (2002) Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci USA 99:10031-10036.
9. Parish CR, Freeman C, Hulett MD (2001) Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta 1471:M99-M108.
10. Nakajima M, Irimura T, Nicolson GL (1988) Heparanases and tumor metastasis. J Cell Biochem 36:157-167.
11. Shafat I, et al. (2007) Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia 9:909-916.
12. Nasser NJ, Avivi A, Shusy M, Vlodavsky I, Nevo E (2007) Cloning, expression, and characterization of an alternatively spliced variant of human heparanase. Biochem Biophys Res Commun 354:33-38.
13. Nasser NJ, et al. (2005) Adaptive evolution of heparanase in hypoxia-tolerant Spalax: Gene cloning and identification of a unique splice variant. Proc Natl Acad Sci USA 102:15161-15166.
14. Nevo E (1999) Mosaic Evolution of Subterranean Mammals: Regression, Progression, and Global Convergence (Oxford Univ Press, London).
15. Nevo E, Ivanitskaya I, Beiles A (2001) Adaptive Radiation of Blind Subterranean Mole Rats (Backhuys, Leiden, The Netherlands).
16. Shams I, Avivi A, Nevo E (2005) Oxygen and carbon dioxide fluctuations in burrows of subterranean blind mole rats indicate tolerance to hypoxic-hypercapnic stresses. Comp Biochem Physiol A Mol Integr Physiol 142:376-382.
17. Arieli R, Nevo E (1991) Hypoxic survival differs between two mole rat species (Spalax ehrenbergi) of humid and arid habitats. Comp Biochem Physiol A 100:543-545.
18. Widmer HR, Hoppeler H, Nevo E, Taylor CR, Weibel ER (1997) Working underground: Respiratory adaptations in the blind mole rat. Proc Natl Acad Sci USA 94:2062-2067.
19. Avivi A, et al. (2005) Increased blood vessel density provides the mole rat physiological tolerance to its hypoxic subterranean habitat. FASEB J 19:1314-1316.
20. Ashur-Fabian O, et al. (2004) Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation. Proc Natl Acad Sci USA 101:12236-12241.
21. Avivi A, Ashur-Fabian O, Amariglio N, Nevo E, Rechavi G (2005) p53, a key player in tumoral and evolutionary adaptation: A lesson from the Israeli blind subterranean mole rat. Cell Cycle 4:368-372.
22. Levy-Adam F, et al. (2005) Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 280:20457-20466.
23. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V (1983) Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: Relationship to tumor cell metastasis. Cancer Res 43:2704-2711.
24. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I (2004) Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96:1219-1230.
25. Shams I, Avivi A, Nevo E (2004) Hypoxic stress tolerance of the blind subterranean mole rat: Expression of erythropoietin and hypoxia-inducible factor 1 α. Proc Natl Acad Sci USA 101:9698-9703.
26. Ast G (2004) How did alternative splicing evolve? Nat Rev Genet 5:773-782.
27. Minn AJ, Boise LH, Thompson CB (1996) Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). J Biol Chem 271:6306-6312.
28. Folkman J (2004) Endogenous angiogenesis inhibitors. Apmis 112:496-507.
29. Finkel E (1999) Potential target found for antimetastasis drugs. Science 285:33-34.
30. Fjeldstad K, Kolset SO (2005) Decreasing the metastatic potential in cancers: Targeting the heparan sulfate proteoglycans. Curr Drug Targets 6:665-682.
31. Lewis KD, et al. (2008) A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 26:89-94.
32. Vlodavsky I, Ilan N, Naggi A, Casu B (2007) Heparanase: Structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13:2057-2073.
33. Yang Y, et al. (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110:2041-2048.